Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment

BACKGROUND: High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by measuring serum regulatory T cell (Treg), serum transfor...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ascierto, Paolo A, Napolitano, Maria, Celentano, Egidio, Simeone, Ester, Gentilcore, Giusy, Daponte, Antonio, Capone, Mariaelena, Caracò, Corrado, Calemma, Rosa, Beneduce, Gerardo, Cerrone, Margherita, De Rosa, Vincenzo, Palmieri, Giuseppe, Castello, Giuseppe, Kirkwood, John M, Marincola, Francesco M, Mozzillo, Nicola
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2010
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2936304/
https://ncbi.nlm.nih.gov/pubmed/20712892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-76
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak